Navigation Links
Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
Date:2/16/2010

l also receive, on a blinded basis, either intravenous placebo or intravenous REOLYSIN. All dosing takes place in the first five days of each cycle with all patients receiving standard intravenous doses of paclitaxel and carboplatin on day one only, and on days one through five, either intravenous placebo or intravenous REOLYSIN at a dose of 3x1010 TCID50. Patients may continue to receive the trial combination therapy for up to eight, 21-day cycles and, thereafter, blinded placebo or blinded REOLYSIN until the patient has progressive disease or meets other criteria for removal from the trial. Oncolytics intends to conduct the first stage of the trial at approximately 25 centres in the U.S., U.K., and Belgium.

The primary endpoint for the trial is overall survival (OS); secondary endpoints include progression free survival (PFS), objective response rate (complete response (CR) + partial response (PR)) and duration of response, and safety and tolerability of REOLYSIN when administered in combination with paclitaxel and carboplatin. The first stage of the trial is designed to enroll 80 patients. The second stage is adaptive, and is designed to enroll between 100 and 400 patients with the most probable statistical enrolment being 195 patients in this stage. This adaptive trial design allows frequent data evaluation to determine if the probability of reaching a statistically significant endpoint has been achieved.

The decision to pursue a Phase 3 trial in head and neck cancers was predicated on positive results seen in the Company's U.K. Phase 1 and Phase 2 combination REOLYSIN and paclitaxel/carboplatin clinical trials, as well as significant preclinical work demonstrating synergy in combination with taxane or platinum-based drugs. Updated results from the U.K. Phase 1/2 trial reported in November 2009 demonstrated an overall response rate (PR and CR) of 42% and a total clinical ben
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 Clintrax ... services located in Raleigh, NC ... Evans as Vice President of Administration. ... will oversee all corporate processes, including their alignment ... Clintrax Global, Brad worked as an HR executive, ...
(Date:8/20/2014)... Livermore, California (PRWEB) August 20, 2014 ... to develop and apply the most complete climate ... challenging and demanding climate change issues. , Eight ... combining forces with the National Center for Atmospheric ... in the new effort. Other participating national laboratories ...
(Date:8/20/2014)... Calif. , Aug. 20, 2014 /PRNewswire-iReach/ -- ... the transformative collaboration between the school,s bioengineering department ... part of the Intel® Software Academic Program, UCSD,s ... sciences and the human body.  ... The study exhibits the work of Dr. ...
(Date:8/19/2014)... August 19, 2014 Shimadzu Scientific ... systems, Prominence-i and Nexera-i, adding to the company’s ... excellent functionality, an intuitive operating environment, and full ... more efficient workflow for conventional to ultra-high-speed analysis. ... intuitive and intelligent design so users can begin ...
Breaking Biology Technology:Clintrax Global, Inc. Announces Addition to Executive Team 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3
... Roche (SWX: ROG.VX; RO.S; OTCQX; RHHBY) today announced that ... accepted for payment all shares validly tendered and not ... shares of common stock of Memory Pharmaceuticals Corp. (Nasdaq: ... cash.As of the expiration of the tender offer, a ...
... Inc.,(Nasdaq: BNVI ) announced today results ... to identify estrogenic drugs that are,safer. The data, ... new regulatory elements can distinguish the estrogenic,pharmacological activity ... prediction of specific tissue effect. , ...
... CHICAGO, Dec. 31 A landmark study published today ... that use of a specially-designed machine to store kidneys ... function when compared to those stored in a traditional ... the LifePort(R) Kidney Transporter monitors the temperature and vascular ...
Cached Biology Technology:Roche Purchases Shares in Tender Offer For Memory Pharmaceuticals Corp. 2Roche Purchases Shares in Tender Offer For Memory Pharmaceuticals Corp. 3Roche Purchases Shares in Tender Offer For Memory Pharmaceuticals Corp. 4Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform 2Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform 3Study Shows Machine Perfusion Significantly Improves Transplant Results 2Study Shows Machine Perfusion Significantly Improves Transplant Results 3
(Date:8/21/2014)... published in the journal Carcinogenesis by researchers ... for the protein adenomatous polyposis coli (APC) in suppressing ... in the U.S. , Lead author Kristi Neufeld, associate ... of the Cancer Biology program at the KU Cancer ... trying to understand the various activities of APC, a ...
(Date:8/21/2014)... in severe abdominal pain, vomiting and systemic inflammation. Every ... with the disease resulting in 1000 deaths. There is ... fluid and nutritional support. , Dr Jason Bruce, ... research, said "The major causes of pancreatitis include bile ... combined with a high fat diet. In fact, the ...
(Date:8/20/2014)... 2014 /CNW/ -  Issue Serious allergic ... become life threatening for some children.    What ... Canadians have food allergies and this number may be increasing, ... are estimated to have food allergies.  The ... and hives to breathing difficulties and loss of consciousness. Symptoms ...
Breaking Biology News(10 mins):Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3Insulin offers new hope for the treatment of acute pancreatitis 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3
... in six will get prostate cancer during his lifetime, making ... a new partnership with Areva Med, UC researchers will investigate ... of prostate cancer tumors. In the study, UC researchers ... efficacy of a new agent targeted against a specific protein ...
... researchers from the Johns Hopkins University School of Medicine ... by European scientific institutions. Andrew P. Feinberg, M.D., ... of the Center for Epigenetics, will receive the honorary ... ceremony in the Stockholm City Hall on May 7. ...
... Researchers in China are reporting that they have found a ... cells -- that have been reprogrammed into a primordial, embryonic-like ... a paper published online last week by the Journal ... the Chinese Academy of Sciences point to a marker they ...
Cached Biology News:UC to test targeted treatment for prostate cancer 22 Hopkins scientists awarded European honorary doctorates 2Chinese scientists discover marker indicating the developmental potential of stem cells 2
... Taq DNA Polymerase is a thermostable recombinant ... in primer extension and other molecular biology ... which provides easy and quick identification of ... allows confirmation of complete mixing. The inert ...
... The EnzChek Lysozyme Assay Kit (E-22013) ... measure levels of lysozyme,activity in solution. ... down to 20 U/mL (Figure 1). ... lysodeikticus cell,walls, which are labeled to ...
RNA oligomers from 10 to 50 bases purified by PAGE and MS-checked. RNAs are supplied dried and fully deprotected....
... (Cap Analog) is used for the synthesis ... vitro transcription reactions. Substitution of cap analog ... in an in vitro transcription reaction results ... into a large fraction of the transcripts. ...
Biology Products: